Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
2006

Study of Capecitabine Therapy in Advanced Cancer

Sample size: 27 publication Evidence: moderate

Author Information

Author(s): D. Santini, B. Vincenzi, G. Schiavon, A. La Cesa, S. Gasparro, A. Vincenzi, G. Tonini

Primary Institution: University Campus Bio-Medico, Rome, Italy

Hypothesis

What is the maximum-tolerated dose of chronomodulated capecitabine in patients with advanced cancer?

Conclusion

High doses of chronomodulated capecitabine can be administered with acceptable toxicity and show evidence of antitumor activity.

Supporting Evidence

  • Patients were assessable for toxicity, with only one episode of dose-limiting toxicity observed.
  • Six partial responses were noted in breast cancer patients and three in colorectal cancer patients.
  • The recommended dose for further studies was established at 2,750 mg/m2.

Takeaway

Doctors tested a new way to give a cancer medicine called capecitabine, and it worked well for many patients without making them too sick.

Methodology

Patients received capecitabine in a specific schedule for two weeks followed by a week of rest, and their responses and side effects were monitored.

Limitations

The study was limited to a small sample size and did not primarily focus on tumor response.

Participant Demographics

Median age was 68 years, with a range of 49 to 88 years; 9 men and 18 women.

Digital Object Identifier (DOI)

10.1186/1471-2407-6-42

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication